Improved assay for total hemolytic complement.

R J Clark; A R Tschida; H Markowitz

Home/Archive/PubMed

PubMed · 3879505

Improved assay for total hemolytic complement.

R J Clark·A R Tschida·H Markowitz

View original source ↗Export metadata ↓

Abstract

Analysis of human serum for total hemolytic complement (CH50) is useful in following the course of patients who have diseases such as lupus nephritis or hypocomplementemic glomerulonephritis. A semi-automated system has been devised that facilitates test performance and reduces cost. An Autoprep dilutor is driven by an Apple IIe microprocessor. Samples are picked up, diluted with buffer, and added to a 96-well flat-bottom Linbro plate in a final volume of 100 microliters. Sensitized sheep RBC (100 microliters) are then added to each well. The plate is incubated at 37 degrees C for 90 min, agitated on a shaker, and then read by a Dynatech MR600 plate reader at 630 nm. The microprocessor converts the reading to percentage hemolysis by utilizing both a buffer blank and a complete hemolysis blank (saponin); these values are applied to the von Krogh equation to yield a CH50 value. Values obtained for normal human serum samples correlate well with those from an established semi-automated method (Technicon) in use in our laboratory.

Explore related subjects

Complement Fixation Tests Complement System Proteins Glomerulonephritis Humans Microcomputers Nephritis Comparative Study Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

R J Clark, A R Tschida, H Markowitz. 1985. Improved assay for total hemolytic complement.. https://pubmed.ncbi.nlm.nih.gov/3879505/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

The present status of the complement fixation test in viral serodiagnosis.

The complement fixation (CF) procedure has played a significant role in the diagnosis of infectious diseases for almost a century. It has accomplished this by functioning in serodiagnosis and by antigen identification particularly in clinical virology. Although it has been replaced by newer, more sensitive and rapid techniques for serodiagnosis, the CF assay is still important as a reference standard for clinical laboratories.

Complement Fixation Tests↗

PubMed1991

Evaluation of a commercial measles virus immunoglobulin M enzyme immunoassay.

Paired serum samples from 93 patients suspected of having measles were assayed for measles virus-specific immunoglobulin M (IgM) antibodies by an enzyme immunoassay (EIA), and the results were compared with results from a complement fixation assay and an EIA for measles virus IgG. By using significant serologic rises as the standard for comparison, the IgM EIA assay had a sensitivity of 85.7%, a specificity of 81.3%, a positive predictive value of 95.7%, and a negative predictive value of 54.2%. This assay can be expected to perform well in outbreak situations.

Complement Fixation Tests↗

PubMed1990

Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine.

The efficacy of a rhesus rotavirus vaccine (MMU 18006, serotype 3) against infantile diarrhea was evaluated by active home surveillance of a group of 320 children 1-10 months of age in Caracas, Venezuela. During a 1 year period following oral administration of vaccine or placebo under a double-masked code, over 600 diarrheal episodes were detected. Etiologic studies revealed that heat-stable toxin (ST) producing enterotoxigenic E. coli (ETEC) was the most common diarrheal agent detected (34%) followed by enteropathogenic E. coli (EPEC, 10.9%), heat-labile toxin (LT) producing ETEC (7.6%), rotavirus (6.9%), Cryptosporidium (4.8%) and Campylobacter (1.3%). ST-producing ETEC were also recovered from over 20% of control stool specimens obtained during diarrhea-free periods, whereas EPEC, rotavirus, Cryptosporidium, and Campylobacter were rarely detected in such control specimens. Rotavirus was responsible for about one-half of the more severe cases of diarrhea. Twenty-two of 151 infants who received placebo (14.6%) and eight of 151 receiving a 10(4) PFU dose of vaccine (5.3%) had rotavirus diarrhea during the follow-up period for an efficacy level of 64% against any rotavirus diarrhea. However, vaccine efficacy reached 90% against the more severe cases of rotavirus diarrhea and was noticeably high in the 1-4 month age group. Serotypic analysis of the rotaviruses detected suggests that the resistance induced by the vaccine was type specific since significant protection was only evident against serotype 3 rotaviruses. A 10(3) PFU dose tested initially in 18 children did not appear to protect against rotavirus diarrhea.

Complement Fixation Tests↗